{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:13Z","timestamp":1793374213348,"version":"4.5.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuro Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1093\/neuonc\/nov152","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T01:00:14Z","timestamp":1440032414000},"page":"1550-1559","source":"Crossref","is-referenced-by-count":166,"title":["Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex"],"prefix":"10.1093","volume":"17","author":[{"given":"Jeffrey P.","family":"MacKeigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy A.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"key":"2015111015264665000_17.12.1550.1","unstructured":"Gomez MR . Varieties of expression of tuberous sclerosis. Neurofibromatosis. 1988;1 (5\u20136):330\u2013338."},{"key":"2015111015264665000_17.12.1550.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00838.x"},{"key":"2015111015264665000_17.12.1550.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.08.001"},{"key":"2015111015264665000_17.12.1550.4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf124"},{"key":"2015111015264665000_17.12.1550.5","doi-asserted-by":"publisher","DOI":"10.1053\/ejpn.2001.0538"},{"key":"2015111015264665000_17.12.1550.6","unstructured":"Novartis Pharmaceuticals Corporation. Afinitor (everolimus tablets for oral administration). Afinitor Disperz (everolimus tablets for oral suspension) [package insert] . East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014."},{"key":"2015111015264665000_17.12.1550.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063564"},{"key":"2015111015264665000_17.12.1550.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100391"},{"key":"2015111015264665000_17.12.1550.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023379"},{"key":"2015111015264665000_17.12.1550.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0445"},{"key":"2015111015264665000_17.12.1550.11","doi-asserted-by":"publisher","DOI":"10.2165\/11634580-000000000-00000"},{"key":"2015111015264665000_17.12.1550.12","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90618-Z"},{"key":"2015111015264665000_17.12.1550.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1994.tb01881.x"},{"key":"2015111015264665000_17.12.1550.14","doi-asserted-by":"publisher","DOI":"10.1038\/ng0294-193"},{"key":"2015111015264665000_17.12.1550.15","unstructured":"Henske EP Scheithauer BW Short MP Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet. 1996;59 (2):400\u2013406."},{"key":"2015111015264665000_17.12.1550.16","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.33.11.962"},{"key":"2015111015264665000_17.12.1550.17","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000280578.99900.96"},{"key":"2015111015264665000_17.12.1550.18","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2008.170"},{"key":"2015111015264665000_17.12.1550.19","doi-asserted-by":"crossref","unstructured":"Hoogeveen-Westerveld M Wentink M van den Heuvel D Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with tuberous sclerosis complex. Hum Mutat. 2011;3 (4):424\u2013435.","DOI":"10.1002\/humu.21451"},{"key":"2015111015264665000_17.12.1550.20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201276"},{"key":"2015111015264665000_17.12.1550.21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201402"},{"key":"2015111015264665000_17.12.1550.22","doi-asserted-by":"publisher","DOI":"10.1086\/316951"},{"key":"2015111015264665000_17.12.1550.23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100136200"},{"key":"2015111015264665000_17.12.1550.24","doi-asserted-by":"publisher","DOI":"10.1042\/BST0370217"},{"key":"2015111015264665000_17.12.1550.25","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20080281"},{"key":"2015111015264665000_17.12.1550.26","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.18.7965-7975.2004"},{"key":"2015111015264665000_17.12.1550.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2006.08.009"},{"key":"2015111015264665000_17.12.1550.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-014-2555-8"},{"key":"2015111015264665000_17.12.1550.29","doi-asserted-by":"crossref","unstructured":"Kwiatkowski DJ Wittemore V Theile E . Pathogenesis of TSC in the brain. In: Crino PB Mehta R Vinters HV , eds. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-Blackwell; 2010:159\u2013185.","DOI":"10.1002\/9783527630073.ch9"},{"key":"2015111015264665000_17.12.1550.30","unstructured":"Lopes MBS Wiestler OD Stemmer-Rachamimov AO Sharma MC . Tuberous sclerosis complex and subependymal giant cell astrocytoma. In: Louis DN Ohgaki H Wiestler OD Cavenee WK , eds. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC Press; 2007:218\u2013221."},{"key":"2015111015264665000_17.12.1550.31","doi-asserted-by":"crossref","unstructured":"Barrows BD Rutkowski MJ Gultekin SH Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma. Turk Patoloji Derg. 2012;28 (2):95\u2013103.","DOI":"10.5146\/tjpath.2012.01107"},{"key":"2015111015264665000_17.12.1550.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2008.00934.x"},{"key":"2015111015264665000_17.12.1550.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.08.002"},{"key":"2015111015264665000_17.12.1550.34","doi-asserted-by":"crossref","unstructured":"Cuccia V Zuccaro G Sosa F Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 2003;19 (4):232\u2013243.","DOI":"10.1007\/s00381-002-0700-2"},{"key":"2015111015264665000_17.12.1550.35","doi-asserted-by":"crossref","unstructured":"de Ribaupierre S Dorfmuller G Bulteau C Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60 (1):83\u201389.","DOI":"10.1227\/01.NEU.0000249216.19591.5D"},{"key":"2015111015264665000_17.12.1550.36","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-010-0025-2"},{"key":"2015111015264665000_17.12.1550.37","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-950391"},{"key":"2015111015264665000_17.12.1550.38","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.658907"},{"key":"2015111015264665000_17.12.1550.39","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.28.721"},{"key":"2015111015264665000_17.12.1550.40","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.28.727"},{"key":"2015111015264665000_17.12.1550.41","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.31.539"},{"key":"2015111015264665000_17.12.1550.42","doi-asserted-by":"publisher","DOI":"10.1139\/y77-007"},{"key":"2015111015264665000_17.12.1550.43","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(83)90012-3"},{"key":"2015111015264665000_17.12.1550.44","unstructured":"Morris RE Wu J Shorthouse R . A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc. 1990;22 (4):1638\u20131641."},{"key":"2015111015264665000_17.12.1550.45","unstructured":"Dilling MB Dias P Shapiro DN Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54 (4):903\u2013907."},{"key":"2015111015264665000_17.12.1550.46","unstructured":"Seufferlein T Rozengurt E . Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996;56 (17):3895\u20133897."},{"key":"2015111015264665000_17.12.1550.47","unstructured":"Clackson T Metcalf C Rivera V Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol. 2003;22. Abstract 882."},{"key":"2015111015264665000_17.12.1550.48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.185"},{"key":"2015111015264665000_17.12.1550.49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-3554-2"},{"key":"2015111015264665000_17.12.1550.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.116"},{"key":"2015111015264665000_17.12.1550.51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.0988"},{"key":"2015111015264665000_17.12.1550.52","doi-asserted-by":"publisher","DOI":"10.1126\/science.1715094"},{"key":"2015111015264665000_17.12.1550.53","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1993.1012"},{"key":"2015111015264665000_17.12.1550.54","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5285.239"},{"key":"2015111015264665000_17.12.1550.55","doi-asserted-by":"publisher","DOI":"10.1038\/nature12122"},{"key":"2015111015264665000_17.12.1550.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02480-6"},{"key":"2015111015264665000_17.12.1550.57","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200101270-00019"},{"key":"2015111015264665000_17.12.1550.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"2015111015264665000_17.12.1550.59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03129.x"},{"key":"2015111015264665000_17.12.1550.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"2015111015264665000_17.12.1550.61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"2015111015264665000_17.12.1550.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"2015111015264665000_17.12.1550.63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0345"},{"key":"2015111015264665000_17.12.1550.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001671"},{"key":"2015111015264665000_17.12.1550.65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"2015111015264665000_17.12.1550.66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"2015111015264665000_17.12.1550.67","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443020-00002"},{"key":"2015111015264665000_17.12.1550.68","unstructured":"Wyeth Pharmaceuticals Inc. Rapamune (sirolimus) oral solution and tablets [package insert] . Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2012."},{"key":"2015111015264665000_17.12.1550.69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-8-1"},{"key":"2015111015264665000_17.12.1550.70","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(00)02116-3"},{"key":"2015111015264665000_17.12.1550.71","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140080-00002"},{"key":"2015111015264665000_17.12.1550.72","doi-asserted-by":"publisher","DOI":"10.1021\/tx900351q"},{"key":"2015111015264665000_17.12.1550.73","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20784"},{"key":"2015111015264665000_17.12.1550.74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10476.x"},{"key":"2015111015264665000_17.12.1550.75","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813488664"},{"key":"2015111015264665000_17.12.1550.76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04212.x"},{"key":"2015111015264665000_17.12.1550.77","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22298"},{"key":"2015111015264665000_17.12.1550.78","doi-asserted-by":"crossref","unstructured":"Cardamone M Flanagan D Mowat D Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 2014;17:631\u2013638.","DOI":"10.1016\/j.jpeds.2013.12.053"},{"key":"2015111015264665000_17.12.1550.79","doi-asserted-by":"publisher","DOI":"10.1177\/0883073808321764"},{"key":"2015111015264665000_17.12.1550.80","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182815428"},{"key":"2015111015264665000_17.12.1550.81","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70489-9"},{"key":"2015111015264665000_17.12.1550.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2013.03.002"},{"key":"2015111015264665000_17.12.1550.83","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23960"},{"key":"2015111015264665000_17.12.1550.84","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0174-9"},{"key":"2015111015264665000_17.12.1550.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2014.03.002"},{"key":"2015111015264665000_17.12.1550.86","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199707150-00008"},{"key":"2015111015264665000_17.12.1550.87","doi-asserted-by":"crossref","unstructured":"Yoon S Ung N Mehta N Medical management with mTOR inhibitors vs surgical resection: comparison of clinical outcomes for subependymal giant cell astrocytomas (SEGA) in tuberous sclerosis complex. Neurol. 2013;80. (Meeting abstracts 1):PL01.001.","DOI":"10.1212\/WNL.80.7_supplement.PL01.001"},{"key":"2015111015264665000_17.12.1550.88","doi-asserted-by":"publisher","DOI":"10.4161\/auto.7.11.17652"},{"key":"2015111015264665000_17.12.1550.89","doi-asserted-by":"publisher","DOI":"10.1002\/aur.132"},{"key":"2015111015264665000_17.12.1550.90","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.07.009"},{"key":"2015111015264665000_17.12.1550.91","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81780-8"},{"key":"2015111015264665000_17.12.1550.92","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0922"},{"key":"2015111015264665000_17.12.1550.93","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5685-08.2009"},{"key":"2015111015264665000_17.12.1550.94","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23098"},{"key":"2015111015264665000_17.12.1550.95","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.246"},{"key":"2015111015264665000_17.12.1550.96","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23124"},{"key":"2015111015264665000_17.12.1550.97","unstructured":"Pfizer. Torisel Kit (temsirolimus) injection, for intravenous infusion only [package insert] . Philadelphia, PA: Pfizer; May 2012."},{"key":"2015111015264665000_17.12.1550.98","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds602"},{"key":"2015111015264665000_17.12.1550.99","unstructured":"European Medicines Agency. Withdrawal assessment report for Jenzyl. December 3, 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/human\/002259\/WC500138917.pdf . Accessed May 21, 2015."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/17\/12\/1550\/7639907\/nov152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T16:48:09Z","timestamp":1718038089000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nov152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":99,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,11,4]]},"published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1093\/neuonc\/nov152"],"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nov152","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]}}}